{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:51:46Z","timestamp":1790095906361,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-242209-BIOSTAT-CHF"],"award-info":[{"award-number":["FP7-242209-BIOSTAT-CHF"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EudraCT 2010-020808-29"],"award-info":[{"award-number":["EudraCT 2010-020808-29"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Whether it affects the use of renin\u2013angiotensin\u2013aldosterone system inhibitors and thereby negatively impacts outcome is unknown. Therefore, we investigated the association between potassium and uptitration of angiotensin-converting enzyme inhibitors (ACEi)\/angiotensin receptor blockers (ARB) and its association with outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Out of 2516 patients from the BIOSTAT-CHF study, potassium levels were available in 1666 patients with HFrEF. These patients were sub-optimally treated with ACEi\/ARB or beta-blockers and were anticipated and encouraged to be uptitrated. Potassium levels were available at inclusion and at 9\u2009months. Outcome was a composite of all-cause mortality and heart failure hospitalization at 2\u2009years. Patients' mean age was 67\u2009\u00b1\u200912\u2009years and 77% were male. At baseline, median serum potassium was 4.3 (interquartile range 3.9\u20134.6) mEq\/L. After 9\u2009months, 401 (24.1%) patients were successfully uptitrated with ACEi\/ARB. During this period, mean serum potassium increased by 0.16\u2009\u00b1\u20090.66\u2009mEq\/L (P\u2009&amp;lt;\u20090.001). Baseline potassium was an independent predictor of lower ACEi\/ARB dosage achieved [odds ratio 0.70; 95% confidence interval (CI) 0.51\u20130.98]. An increase in potassium was not associated with adverse outcomes (hazard ratio 1.15; 95% CI 0.86\u20131.53). No interaction on outcome was found between baseline potassium, potassium increase during uptitration, or potassium at 9\u2009months and increased dosage of ACEi\/ARB (Pinteraction\u2009&amp;gt;\u20090.5 for all).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher potassium levels are an independent predictor of enduring lower dosages of ACEi\/ARB. Higher potassium levels do not attenuate the beneficial effects of ACEi\/ARB uptitration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.1079","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T05:52:39Z","timestamp":1515736359000},"page":"923-930","source":"Crossref","is-referenced-by-count":70,"title":["Potassium and the Use of Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data from BIOSTAT-CHF"],"prefix":"10.1093","volume":"20","author":[{"given":"Joost C.","family":"Beusekamp","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]},{"name":"National Heart Centre Singapore \u00a0","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haye H.","family":"van der Wal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany"]},{"name":"Division of Cardiology and Metabolism-Heart Failure, Cachexia and Sarcopenia, Department of Cardiology, and Berlin-Brandenburg Center for Regenerative Therapies, Charit\u00e9 University Medicine , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[{"name":"University of Bergen , Bergen ,","place":["Norway"]},{"name":"Stavanger University Hospital , Stavanger ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine and Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"van der Harst","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L.","family":"Hillege","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim C.","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School , Dundee ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong L.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK, and NIHR Leicester Biomedical Research Centre, Glenfield Hospital , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Heart Diseases, Wroclaw Medical University, Poland, and Cardiology Department, Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh J.","family":"Samani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK, and NIHR Leicester Biomedical Research Centre, Glenfield Hospital , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeilko H.","family":"Zwinderman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Inserm CIC-P 1433, Universit\u00e9 de Lorraine, CHRU de Nancy, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm CIC-P 1433, Universit\u00e9 de Lorraine, CHRU de Nancy, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"2026011721234447700_ejhf1079-bib-0001","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0002","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"2026011721234447700_ejhf1079-bib-0003","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"2026011721234447700_ejhf1079-bib-0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011721234447700_ejhf1079-bib-0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026011721234447700_ejhf1079-bib-0006","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0007","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","article-title":"Clinical epidemiology of heart failure","volume":"93","author":"Mosterd","year":"2007","journal-title":"Heart"},{"issue":"11 Suppl","key":"2026011721234447700_ejhf1079-bib-0008","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin\u2013angiotensin\u2013aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2026011721234447700_ejhf1079-bib-0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between serum potassium and outcomes in patients with reduced kidney function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026011721234447700_ejhf1079-bib-0011","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/pgmj.2008.072058","article-title":"Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism","volume":"86","author":"Poggio","year":"2010","journal-title":"Postgrad Med J"},{"key":"2026011721234447700_ejhf1079-bib-0012","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.11904","article-title":"Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"314","author":"Cooper","year":"2015","journal-title":"JAMA"},{"key":"2026011721234447700_ejhf1079-bib-0013","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/archinternmed.2012.2514","article-title":"Improved outcomes in heart failure treated with high-dose ACE inhibitors and ARBs: a population-based study","volume":"172","author":"Egiziano","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026011721234447700_ejhf1079-bib-0014","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","article-title":"Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials)","volume":"119","author":"Tromp","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026011721234447700_ejhf1079-bib-0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0016","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","article-title":"What is the optimal serum potassium level in cardiovascular patients?","volume":"43","author":"Macdonald","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026011721234447700_ejhf1079-bib-0017","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0018","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026011721234447700_ejhf1079-bib-0019","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0021","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","article-title":"Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)","volume":"115","author":"Khan","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026011721234447700_ejhf1079-bib-0022","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/eurheartj\/ehm091","article-title":"A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure","volume":"28","author":"Ahmed","year":"2007","journal-title":"Eur Heart J"},{"key":"2026011721234447700_ejhf1079-bib-0023","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.688","article-title":"Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia","volume":"19","author":"Rossignol","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0024","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.109.899526","article-title":"Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies","volume":"3","author":"Bowling","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026011721234447700_ejhf1079-bib-0026","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011721234447700_ejhf1079-bib-0027","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026011721234447700_ejhf1079-bib-0028","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","article-title":"Association between renin\u2013angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study","volume":"36","author":"Edner","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721234447700_ejhf1079-bib-0029","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/eurheartj\/ehv300","article-title":"Is substantial renal dysfunction in patients with heart failure no longer a contraindication for RAS inhibition? The power of a large, high-quality registry to illuminate major clinical issues","volume":"36","author":"Dickstein","year":"2015","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/20\/5\/923\/66269271\/eurjhf_20_5_923.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/20\/5\/923\/66269271\/eurjhf_20_5_923.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:26:12Z","timestamp":1768703172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/20\/5\/923\/8414712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,1,12]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1079","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5]]},"published":{"date-parts":[[2018,1,12]]}}}